ROXALEM rivaroxaban 10 mg film-coated tablet blister pack

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

rivaroxaban, Quantity: 10 mg

Disponible desde:

Alembic Pharmaceuticals Australia Pty Ltd

formulario farmacéutico:

Tablet, film coated

Composición:

Excipient Ingredients: magnesium stearate; lactose monohydrate; croscarmellose sodium; hypromellose; sodium lauryl sulfate; microcrystalline cellulose; titanium dioxide; purified talc; macrogol 6000; iron oxide red

Vía de administración:

Oral

Unidades en paquete:

30 tablets, 15 tablets, 10 tablets

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Rivaroxaban is indicated for:,? Prevention of venous thromboembolism (VTE) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks),? Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke,? Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for the prevention of recurrent DVT and PE,Rivaroxaban, in combination with aspirin, is indicated for:,? The prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD)

Resumen del producto:

Visual Identification: Round shaped, pink, film-coated biconvex tablets debossed with 503 on one side and plain on the other side. Approximately 5 mm in diameter and 3 mm in thickness.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Estado de Autorización:

Registered

Fecha de autorización:

2023-10-03